Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
KHTRF
Primary Symbol:
T.GUD
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 10, 2022 2:25pm
RE:Only 200 shares traded @ 10:15
Actually Golden ... if you look at the top of this Stockhouse siite - to the right of the GUD share price, you will see the bid/ask identified. If one of those is replaced by a red circle with a
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Sep 09, 2022 10:16am
Only 200 shares traded @ 10:15
Is there a halt? News pending? just curious.
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Sep 08, 2022 3:09pm
RE:buybacks
Interesting! 5.7962 was the highest price they paid (for 100,000 shares).
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Sep 08, 2022 11:50am
Population to double or greater in 8 years needing Exelon
in Brazil alone! In recent post states the rapidly growing need for products just reintroduced in Brazil! Add to that all the other South American Countries that will be able to benefit from Exelon
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Sep 08, 2022 8:24am
RE:buybacks
The dream ...the inpossible dream .............ho....paladinho....paladin Mug/Gold lost a fortunes waitng for you
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Sep 07, 2022 4:31pm
buybacks
Filed 2022-09-07 15:21 Tx date 2022-08-31 $GUD Knight Therapeutics Inc. Knight Therapeutics Inc. 1 - Issuer Direct Ownership
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 07, 2022 1:43pm
RE:Paladin labs comparison to Knight
Roughly, Paladin was in business for 14 years at that point - if your numbers are correct (looks correct). Knight is in it's 8th year. Knight is in 11 countries and we have EXELON rights in 15 or
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Sep 07, 2022 11:58am
Paladin labs comparison to Knight
In 2011, Paladin recorded revenues of $141.5 milliion, a RECORD revenue increase of 11% YOY! In 2021, Knight Therapeutics recorded record revenuew of $243.5 Million, a RECORD revnue increase of 22
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Sep 04, 2022 6:24pm
RE:RE:Fund Investments
Mad Mug when will u undestand that lame horses never come back? It is done it is over. 10 years is a long time use tax loses and move on. Bet the rest of the few dimes on ATE
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 02, 2022 11:39am
RE:Fund Investments
Yes - but at these prices - much less effect (dollar wise) on the bottom line from Singular. Likely hidden in the numbers - much smaller effect now vs. growth from Exelon, etc.
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Sep 02, 2022 9:06am
Fund Investments
I guess we should prepare for some more fund losses. SGS is down 33% from the end of June (-34% within the past month!). Meanwhile REPL up by about 9%..
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Aug 31, 2022 6:10pm
RE:ENDO
There's 53 drugs at Paladin that GUD might be interested in (at the right price). Anacin Pensaid Tempra etc ... Interesting - they used to have 69 drugs (last year). The offering size is down by
...more
(8)
•••
wofats
X
View Profile
View Bullboard History
Post by
wofats
on Aug 31, 2022 1:44pm
ENDO
Are all these drugs and accessories up for grabs now? I think ENDO has stopped trading and there is a void that will be filled . Branded Pharmaceuticals, Sterile Injectables, Generic
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Aug 26, 2022 12:55am
Indications ... EXELON (Rivastigmine)
Wonder if there are other opportunities where GUD might look to use EXELON in the future. Rivastigmine is used to treat dementia (a brain disorder that affects the ability to remember, think clearly,
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario